Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

HUMA stock hub

Humacyte, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

HUMAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

235.3M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

HUMA

In the news

Latest news · HUMA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-137.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All HUMA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001818382
Company name	Humacyte, Inc.
Country	United States
Country code	US
Cusip	44486Q103
Employees	184
Employees Change	-36%
Employees Change Percent	-16.36
Enterprise value	$250.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US44486Q1031
Last refreshed	2026-05-10
Market cap	$235.3M
Market cap category	Micro-Cap
Price	$1.06
Price currency	USD
Rev Per Employee	11,076.09x
Sector	Healthcare
Sic	2836
Symbol	HUMA
Website	https://www.humacyte.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-17.35%
EV Sales Forward	21.96x
EV/Sales	122.76x
FCF yield	-45.01%
P/B ratio	65.81x
P/S ratio	115.48x
PS Forward	20.65x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-76.4M
Net Income	$-40.8M
Net Income Growth Years	1%
Pretax Margin	-2,003.58%
Profit Per Employee	$-221,918
ROA	-52.82
Roa5y	-38.07
ROCE	-109.6
ROIC	-137.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-13.12%
Cagr3y	-38.73%
Cagr5y	-36.17%
EPS Growth Quarters	5
EPS Growth Years	1
Revenue Growth Years	0x
Revenue Growth3 Y	9.2x
Revenue Growth5 Y	6.45x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.02
Assets	$116.4M
Cash	$50.5M
Current Assets	$67.8M
Current Liabilities	$18.4M
Debt	$65.3M
Debt Equity	$21.02
Equity	$3.1M
Interest Coverage	-9.55
Liabilities	$113.3M
Long Term Assets	$48.6M
Long Term Liabilities	$94.9M
Net Cash	$-14.8M
Net Cash By Market Cap	$-6.31
Net Debt Equity	$4.78
Tangible Book Value	$3.1M
Tangible Book Value Per Share	$0.02
WACC	16.21

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.69
Net Working Capital	$1.4M
Quick ratio	2.77
Working Capital	$49.4M
Working Capital Turnover	$0.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-33.49%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-13.11%
200-day SMA	1.31
3Y total return	-77.01%
50-day SMA	0.86
50-day SMA vs 200-day SMA	50under200
5Y total return	-89.4%
All Time High	17.45
All Time High Change	-93.93%
All Time High Date	2021-09-01
All Time Low	0.55
All Time Low Change	93.82%
All Time Low Date	2026-03-30
ATR	0.08
Beta	2.31
Beta1y	5.04
Beta2y	2.93
Ch YTD	10.36
High	1.09
High52	2.93
High52 Date	2025-06-06
High52ch	-63.82%
Low	1.01
Low52	0.55
Low52 Date	2026-03-30
Low52ch	93.82%
Ma50ch	22.88%
Premarket Change Percent	-1.85
Premarket Price	$1.06
Premarket Volume	78,814
Price vs 200-day SMA	-18.96%
RSI	68.52
RSI Monthly	41.63
RSI Weekly	47.75
Sharpe ratio	0.4x
Sortino ratio	0.67
Total Return	-33.49%
Tr YTD	10.36
Tr1m	74.66%
Tr1w	23.93%
Tr3m	12.97%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	3
Analyst Price Target Top	$1.67
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.11
Earnings Revenue Estimate	1,417,600x
Earnings Revenue Estimate Growth	174.2x
Operating Income	$-107.4M
Operating margin	-5,271.7
Price target	$6.19
Price Target Change	$484
Price Target Change Top	$57.55

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	190,861,929%
Float Percent	85.97%
Net Borrowing	36,984,000
Shares Insiders	4.26%
Shares Institutions	28.26%
Shares Out	222,019,108
Shares Qo Q	17.98%
Shares Yo Y	33.49%
Short Float	23.5%
Short Ratio	4.56
Short Shares	20.2

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-115.7M
Average Volume	4,695,294.4x
Bv Per Share	0.02
CAPEX	$-884,000
Ch1m	74.66
Ch1w	23.93
Ch1y	-13.11
Ch3m	12.97
Ch3y	-77.01
Ch5y	-89.4
Ch6m	-20.3
Change	-1.85%
Change From Open	-0.93
Close	1.08
Days Gap	-0.93
Depreciation Amortization	7,345,000
Dollar Volume	5,923,810
Earnings Date	2026-05-13
Earnings Time	bmo
EBIT	$-107.4M
EBITDA	$-100.1M
EPS	$-0.26
F Score	2
FCF	$-105.9M
FCF EV Yield	-42.34x
FCF Per Share	$-0.48
Financing CF	61,486,000
Fiscal Year End	December
Founded	2,004
Investing CF	-884,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-27
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-27
Ma150	1.14
Ma150ch	-7.02%
Ma20	0.8
Ma20ch	31.91%
Net CF	-44,440,000
Next Earnings Date	2026-05-13
Open	1.07
Optionable	Yes
Position In Range	62.5
Post Close	1.06
Postmarket Change Percent	-0.94
Postmarket Price	$1.05
Ppne	47,690,000
Pre Close	1.08
Price Date	2026-05-08
Ptbv Ratio	75.7
Relative Volume	1.19x
Revenue	2,038,000x
SBC By Revenue	478.56x
Share Based Comp	9,753,000
Tr6m	-20.3%
Us State	North Carolina
Volume	5,588,500
Z Score	-9.48

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does HUMA pay a dividend?

Capital-return profile for this ticker.

Performance

HUMA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns HUMA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+28.3%

Float: +86.0% of shares outstanding

Insider ownership

+4.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

HUMA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

68.5

Neutral momentum band

Price vs 200-day MA

-19.0%

50/200-day relationship not available

Beta (5Y)

2.31

More volatile than the market

Sharpe ratio

0.40

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About HUMA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current HUMA stock rating?

Humacyte, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full HUMA analysis?

The full report lives at /stocks/HUMA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for HUMA?

The latest report frames HUMA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the HUMA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.